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Abstract 22 
Introduction: Low fat free mass index (FFMI) is a component of the ESPEN diagnosis criteria 23 
of malnutrition, that only when accompanied with weight loss is considered to be a determinant 24 
of malnutrition. Our aims were to assess the prevalence of malnutrition in patients with chronic 25 
obstructive pulmonary disease (COPD) applying the ESPEN criteria, and to examine the ability 26 
of different components of the criteria to predict COPD severity, length of stay (LOS), 27 
hospital readmissions within 30 days and mortality.  28 
Methods: Subjects were COPD patients (n=121) admitted to Landspitali University Hospital 29 
from March 2015-March 2016. Patients were screened for nutritional risk using Icelandic 30 
screening tool (ISS) and NRS-2002. Body composition was measured by bioelectrical impedance 31 
analysis (BIA). Lung function was measured by spirometry.  32 
Results: The prevalence of malnutrition according to the ESPEN criteria was 21%. The 33 
association between nutritional assessment, applying different components of the ESPEN 34 
criteria, and COPD severity was highly significant, with the highest risk being associated with 35 
low FFMI OR (95% CI) 4.77 (2.03, 11.20; p<0.001). There was a trend towards higher risk of 36 
hospitalization for >7 days in subjects with low FFMI (OR 2.46 95% CI 0.92, 6.59; p=0.074) and   37 
increased risk of 6 and 9 months’ mortality (OR 2.72 95% CI 0.88, 8.39, P=0.082 and OR 2.72 38 
95% CI 0.94, 7.87, P=0.065, respectively) in subjects diagnosed as malnourished by the ESPEN 39 
criteria. 40 
Conclusion: This study describes the prevalence of malnutrition in hospitalized COPD patients 41 
using the ESPEN criteria from 2015. Our findings suggest that FFMI could be used 42 
independently of weight loss for the diagnosis of malnutrition in COPD patients, although there 43 
remain some problems associated with its measurement in the clinical setting. 44 
 45 
Keywords: Malnutrition; COPD; ESPEN malnutrition definition; Nutritional screening  46 
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Introduction 48 
For several years screening for nutritional risk has been recommended by national and 49 
international societies for clinical nutrition (Kondrup, Allison, et al., 2003) and different tools 50 
have been validated during the past decades (Kondrup, Rasmussen, Hamberg, Stanga, & Ad 51 
Hoc, 2003; Thorsdottir, Gunnarsdottir, & Eriksen, 2001). Studies have defined a large proportion 52 
of patients with chronic obstructive pulmonary disease (COPD) as at nutritional risk, but the 53 
prevalence varies (20-45%) depending on which screening tool is used (Collins, Elia, 54 
Kurukulaaratchy, & Stratton, 2016; Hogan, Lan, Diep, Gallegos, & Collins, 2016; Thorsdottir et 55 
al., 2001; Vermeeren et al., 2006). Most commonly used screening tools rely on assessment of 56 
height and body weight, and calculations of body mass index (BMI). Although BMI has been 57 
shown to be an independent risk factor in the prognosis of COPD (Schols, Slangen, Volovics, & 58 
Wouters, 1998) and overall mortality (Hallin et al., 2007), with increased risk of mortality even 59 
in patients with normal BMI compared to those with higher BMI (Cao et al., 2012; Guo et al., 60 
2016), it does not take into account variations in body composition. Age-related loss of muscle, 61 
also known as sarcopenia, has been reported in 15% of COPD patients (Jones et al., 2015) and 62 
cachexia is a common feature of COPD associated with an increased risk of mortality (Sanders, 63 
Kneppers, van de Bool, Langen, & Schols, 2016; von Haehling & Anker, 2014; Wagner, 2008). 64 
Therefore, the use of body composition measurements in the assessment of nutritional risk that 65 
enable separation of fat mass and the fat free mass components in patients with COPD might be 66 
relevant (Gologanu, Ionita, Gartonea, Stanescu, & Bogdan, 2014; Mamoto et al., 2003). A recent 67 
statement from the European Society for Clinical Nutrition and Metabolism (ESPEN) based on 68 
unanimous consensus of 12 experienced clinical scientists encouraged the development of 69 
accessible techniques for body composition measurements in all health care settings (Cederholm 70 
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et al., 2015), and proposed new diagnostic criteria for recognition of malnutrition. The definition 71 
differs from previous diagnostic criteria as it combines weight loss with either age related BMI 72 
or fat free mass index (FFMI) (Cederholm et al., 2015) as a second alternative to low BMI 73 
(<18.5 kg/m2) for diagnosis of malnutrition. Few studies have used these new criteria (Rojer et 74 
al., 2016; Sanz-Paris et al., 2016) and none in patients with COPD.  75 
The aims of the present study were to assess the prevalence of malnutrition in patients with 76 
chronic obstructive pulmonary disease (COPD) applying the ESPEN criteria, and to examine the 77 
ability of different components of the criteria to predict severity of COPD, length of stay (LOS), 78 
hospital readmissions within 30 days and mortality.    79 
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Materials and Methods  80 
Subjects 81 
Subjects were patients with COPD admitted to the Department of Pulmonary Medicine at 82 
Landspitali during one year: March 2015- March 2016 (n=236). The most common reason for 83 
admission was exacerbation of COPD. Patients who were judged to be able to maintain balance 84 
on a device to measure body composition and had an anticipated length of hospitalization of >3 85 
days (evaluated by medical staff in the department) were invited to participate. Information on 86 
height was collected from electronic medical records in Landspitali (SAGA (TM software 87 
3.1.39.9)).  88 
Socio-demographic data, date of admission, readmission within 30 days, LOS and mortality at 89 
six and nine months, were collected from electronic medical records SAGA (TM software 90 
3.1.39.9). 91 
Nutritional risk screening  92 
For each patient, nutritional screening was undertaken by a trained researcher on admission using 93 
the following screening tools. 94 
Icelandic simple screening (ISS) 95 
This screening tool is recommended by the clinical guidelines for hospital nutrition at 96 
Landspitali (Friðriksdóttir, 2011) and was validated against a full nutritional assessment (weight, 97 
height, BMI, serum albumin, pre-albumin, lymphocyte count, triceps skinfold thickness, mid-98 
arm muscle circumference, and unintentional weight loss) in COPD patients (Thorsdottir et al., 99 
2001) (appendix 1). Nutritional risk is categorized as low (score 0-1), medium (score 2-3) and 100 
high (score ≥ 4). A total score of ≥4 is considered ‘at nutritional risk’.  101 
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Nutritional Risk Screening (NRS-2002) 102 
The NRS-2002 screening tool was developed by Danish Society for Parenteral and Enteral 103 
Nutrition, recommended by ESPEN and validated using retrospective analysis of 128 104 
randomized controlled trials of nutritional support in different patient groups (Kondrup, 105 
Rasmussen, et al., 2003) (appendix 2). Patients are scored in each of two categories according to 106 
whether key features are absent (score 0), mild (score 1), moderate (score 2) or severe (score 3), 107 
giving a total possible score of 0-6. If patients are  ≥ 70 years, 1 point is added to the final score. 108 
With a total score of ≥3 a patient is considered ‘at nutritional risk’. 109 
ESPEN criteria for the diagnoses of malnutrition  110 
The two alternative ways to diagnose malnutrition proposed by the new ESPEN criteria are 111 
summarized in the Fact box. These criteria may be applied after patients have been screened 112 
using a validated screening tool to identify those at risk of malnutrition. The data collected on 113 
nutritional status and body composition were used to separate patients into groups according to 114 
the proposed cut-offs.   115 
Body composition  116 
A portable, multi- frequency (20kHz, 100kHz) bioelectrical impedance analysis (BIA) device 117 
(InBody230 Co., Ltd. Korea) was used to measure body composition. The method, based on a 118 
low electrical current sent through the body to measure the tissue impedance, has previously 119 
been validated in stable COPD patients (Schols, Broekhuizen, Weling-Scheepers, & Wouters, 120 
2005).  121 
The device measures a patient’s weight, estimates total body water, fat mass and fat free mass, 122 
and calculates BMI. The BIA measurement was performed by the same trained researcher in the 123 
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morning, after breakfast within 48 hours from enrolment to the study. FFMI was calculated as 124 
fat free mass divided by height squared in kg/m2 (Schutz, Kyle, & Pichard, 2002). 125 
Classification of disease severity 126 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured 127 
by spirometry (Jaeger MS-PFT®, Care Fusion, San Diego, USA) and disease severity was 128 
classified using the GOLD criteria (Pauwels et al., 2001). Mild (GOLD 1): FEV1≥80 percent 129 
predicted, moderate (GOLD 2): 50 percent ≤ FEV1<80 percent predicted, severe (GOLD 3): 30 130 
percent ≤ FEV1 <50 percent predicted and very severe (GOLD 4): FEV1 <30 percent predicted. 131 
The measurement was carried out by a trained researcher towards the end of the hospital stay.  132 
Statistical analysis 133 
For statistical analyses IBM SPSS Statistics 24 was used and the level of significance was set at 134 
0.05. The Kolmogorov-Smirnov test was used to test normality of data. Descriptive analyses 135 
were presented as means ± SD. Linear regression analyses were used to determine the 136 
association between different variables (exposure) related to nutritional assessment: malnutrition 137 
according to ESPEN diagnostic criteria, nutritional risk using two validated screening tools (ISS 138 
and NRS-2002), each component of the ESPEN diagnostic criteria (unintentional weight loss, 139 
age related BMI below cut offs and low FFMI) and disease severity, LOS, six and nine month 140 
mortality and 30-day readmission (outcomes). According to policy at Landspitali, the aim is that 141 
mean LOS should not exceed 7 days, therefore this was used as the cut-off in our analyses. 142 
Adjustments were made for potential confounding variables, such as gender and lung function. 143 
Cohen´s kappa (K) was used to determine the agreement between the screening tools (ISS and 144 
NRS-2002) and between each screening tool and ESPEN diagnostic criteria for malnutrition. 145 
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Kappa is categorized by the strength of agreement as Slight (<0.20), Fair (0.21-0.40), Moderate 146 
(0.41-0.60), Substantial (0.61-0.80) and Almost perfect (0.81–1.00) (Viera & Garrett, 2005).  147 
Ethics 148 
The study was approved by the hospital's Bioethics Committee (reference nr. 12/2015) and the 149 
medical manager at Landspitali (16, LSH 28-15). Informed written consent was obtained prior to 150 
inclusion in the study. If patients were at nutritional risk, appropriate nutritional support was 151 
provided e.g. energy- and protein dense food and/or oral nutritional supplement (ONS) and/or 152 
dietary advice. 153 
Results  154 
A total of 236 patients were screened for nutritional risk during the study period. Of these, 29 155 
(12%) refused to participate and another 70 (30%) patients were not eligible due to a planned 156 
admission of less than three days (n=19). A further forty-two (18%) patients were excluded as 157 
they were not able to stand in an upright position for 60 seconds (the time it takes to measure 158 
body composition using BIA) or judged by the nursing staff to be too sick to be able to 159 
participate. Nine patients were not eligible for other reasons e.g. cognitive impairment. Of those 160 
who did not participate in the study, 99 (34%) were defined as at nutritional risk when using the 161 
screening tool proposed by Landspitali University hospital (referred to as ISS). Prevalence of 162 
nutritional risk in the group defined as not being eligible due to sickness was 18 (43%).   163 
One hundred and thirty-seven patients (58.5%) consented to participate. However, 16 (12%) had 164 
insufficient data available (measurement of body composition) e.g. due to admission to the ICU, 165 
edema, not able to stand in an upright position for measuring BIA. Data were analysed for 121 166 
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participants (69 women and 52 men) for whom complete data on screening and body 167 
composition was available. A flowchart of recruitment is shown in Figure 1.  168 
Baseline characteristics 169 
Data on anthropometric and functional measurements for all participants included in the final 170 
sample (n=121) are shown in Table 1. Data on FEV1were available for 98 (81%) of the 121 171 
subjects and off those, 56 (57%) had severe or very severe disease. Fifty-nine (48%) subjects 172 
were classified by BMI as overweight or obese and 36 (30%) had low FFMI.  173 
Prevalence of malnutrition 174 
Nutritional screening using the ISS identified 44 (36%) patients as being at nutritional risk 175 
(Table 2). The more widely used screening tool, NRS-2002, identified more patients at 176 
nutritional risk than the ISS (n=67 (55%)). Table 2 shows the number (%) of patients who 177 
following screening with ISS or NRS-2002 had measurements below the cut-off values 178 
suggested by the two alternatives of the ESPEN diagnostic criteria. The number of subjects 179 
diagnosed as malnourished was very similar applying the two different screening tools (n=25 180 
(21% of all subjects, 57% of those defined as risk by ISS) vs. n=23 (19% of all subjects and 181 
34%, of those defined at risk by NRS2002). Applying the ESPEN criteria without screening for 182 
nutritional risk first resulted in the same number of subjects diagnosed as malnourished as when 183 
applying screening prior to diagnosis, in line with the protocol proposed by ESPEN.  184 
A moderate agreement between the two screening tools used in our study was seen by Cohen’s 185 
kappa analysis (K=0.470, p < 0.001). Substantial agreement was seen between the ISS and the 186 
ESPEN criteria of malnutrition (K=0.626, p < 0.001) while the agreement between NRS-2002 187 
and the ESPEN criteria of malnutrition was fair (K=0.285, p < 0.001).  188 
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Eight subjects who were found to have a low FFMI were not considered to be at nutritional risk 189 
by screening. These subjects did not report weight loss in the past months and had a significantly 190 
higher BMI than subjects with low FFMI defined at nutritional risk (23.5±2.6 vs. 17.9±2.0, 191 
p<0.001) (supplemental table 4). 192 
Outcomes 193 
COPD severity 194 
The association between nutritional status (defined by two different screening tools and each 195 
alternative of the ESPEN criteria) and severity of COPD was highly significant, with low FFMI 196 
being the variable associated with the highest risk of being at a severe or very severe stage of the 197 
disease (OR 4.77 95% CI 2.03, 11.20; p<0.001) (Table 3). Unintentional weight loss was not 198 
found to be associated with severity of COPD in our study. 199 
Length of stay and readmissions 200 
Higher risk of prolonged hospitalization (>7 days) was seen in subjects with low FFMI (OR 2.46 201 
95% CI 0.92, 6.59; p=0.074), although the results were not statistically significant (Table 3). No 202 
associations were found between each alternative of the ESPEN diagnosis for malnutrition or 203 
nutritional risk by the ISS or NRS-2002 and readmission within 30 days. 204 
Mortality 205 
Being defined as at nutritional risk by the Icelandic screening sheet (ISS) was found to predict 206 
mortality within 6 and 9 months from admission to the hospital (OR 3.48 95% CI 1.12, 10.37, 207 
P=0.025 and OR 2.88 95% CI 1.06, 7.82, P=0.039, respectively). Unintentional weight loss also 208 
independently predicted mortality 6 months after hospitalization (OR 3.88 95% CI 1.14, 13.26, 209 
P=0.030). However, these associations did not remain statistically significant after adjusting for 210 
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lung function. Being defined at nutritional risk by NRS-2002 was not associated with increased 211 
risk of mortality, while a trend towards increased risk was observed among those diagnosed 212 
malnourished by ESPEN criteria. 213 
Discussion  214 
The present study describes the prevalence of malnutrition in hospitalized COPD patients 215 
according to the new ESPEN diagnostic criteria for malnutrition. Twenty-five (21%) of patients 216 
were categorized as malnourished, although interestingly, in our study sample, use of nutritional 217 
screening prior to applying the ESPEN criteria did not result in recognition of any more patients 218 
than applying the ESPEN criteria directly without the screening step. Eight subjects (1%) were 219 
found to have low FFMI but were not considered to be at nutritional risk by screening. This 220 
raises questions about whether FFMI should be part of nutritional screening which is often 221 
undertaken by staff with fewer skills in nutritional assessment. Despite the limited data set used 222 
in nutritional screening there are often difficulties in getting screening completed reliably in 223 
many places. If low FFMI is indicative of nutritional risk in the absence of change in the other 224 
parameters of nutritional screening, this raises questions about the skills needed in those 225 
conducting screening. On average, this group had a higher BMI than subjects with low FFMI 226 
defined at nutritional risk by nutritional screening (23.5±2.6 vs. 17.9±2.0, p<0.001). It has been 227 
shown that even patients with a normal BMI have increased risk of mortality compared to those 228 
with higher BMI (Cao et al., 2012; Guo et al., 2016). The use of such low BMI cut-off (<18.5 229 
kg/m2) as suggested in the ESPEN diagnostic criteria in a disease characterized by wasting might 230 
not be suitable. In our study, patients with low FFMI (<15 and 17 kg/m2 in women and men, 231 
respectively) but not identified as at nutritional risk had a mean BMI of 23.5 kg/m2 but the 232 
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number of patients was small and further studies are needed to investigate this in the COPD 233 
population. 234 
In our study, we found a strong association between FFMI and severity of COPD. Previous 235 
studies have reported low FFMI as a useful predictor of disease severity and mortality (Luo et 236 
al., 2016; Schols et al., 2005; Slinde, Gronberg, Engstrom, Rossander-Hulthen, & Larsson, 237 
2005). Our results and reports from other studies raises the question as to whether FFMI should 238 
be used as an independent criterion for diagnosis of malnutrition in COPD as changes in body 239 
compositions can occur well before any weight loss (Schols et al., 1998) In our study, using 240 
FFMI independently would have resulted in eight additional patients recognized as malnourished 241 
using the ESPEN criteria, and without measuring FFMI it is likely that some patients with 242 
normal or even high BMI would go undetected despite being muscle depleted (Vermeeren et al., 243 
2006). 244 
The aetiology of malnutrition in COPD is complex and it is difficult to determine whether FFM 245 
depletion results from changes to nutritional status or to disease processes which might have 246 
implications for the nutritional management of patients. Inflammation is a reaction to many 247 
diseases, including COPD, which can lead to substantial loss of FFM. If inflammation markers 248 
like C-reactive protein (CRP) and transthyretin (pre-albumin) are not taken into account in the 249 
diagnosis of malnutrition it is hard to prioritize treatment and to know if any potential benefits 250 
are from the nutritional therapy or other medical treatment (Soeters et al., 2016). However, 251 
successful dietary intervention in this patient group, have been demonstrated, with low quality 252 
evidence from RCTs mainly in patients with stable COPD of improvements in FFM, suggesting 253 
that nutritional depletion is not entirely an epiphenomenon of the disease (Ferreira, Brooks, 254 
White, & Goldstein, 2012).  255 
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In some recent studies using the new ESPEN criteria information on FFMI is lacking (Poulia et 256 
al., 2016; Sanz-Paris et al., 2016). It is a limitation of the current study that BIA is not the gold 257 
standard method for measuring body composition and not validated in hospitalized patients who 258 
sometimes may have fluid disturbance. However, BIA is quick and inexpensive compared to 259 
many other methods and in the ESPEN consensus statement (Cederholm et al., 2015) the use of 260 
any technical devices like BIA are approved for measuring FFM. Another limitation to the BIA 261 
method used in this study is that it depends on the ability to stand for 60 seconds. In our study, 262 
42 patients (18% of the total number of patients recruited to the hospital in the study period) 263 
were excluded from participation as they were not stable enough to stand on the device. A 264 
different device would therefore be required if measurements of FFMI were to be used in routine 265 
clinical practice. 266 
The two screening tools used in the present study were developed with quite similiar aims in 267 
mind. The Icelandic tool was validated in COPD patients with the aim of identifying patients that 268 
require further nutritional assessment and treatment, and the NRS-2002 was designed to identify 269 
hospitalized patients likely to benefit from nutritional support not only to find those who are 270 
likely to be at nutritional risk. However, there are some differences between the two tools which 271 
may explain the large difference in the proportion of patients found to be at nutritional risk in 272 
this study. For example, the NRS-2002 adds 1 point to the score for having COPD, therefore all 273 
of our subjects received this point. Another difference is that the question; "Has the patient been 274 
hospitalised for 5 days or more during previous 2 months?" is included in the ISS but not in 275 
NRS-2002, which might partly explain the association seen between nutritional risk by ISS and 276 
mortality in the present study. Interestingly, NRS-2002 failed to recognize 2 patients, identified 277 
by ISS at nutritional risk and ESPEN as malnourished. Again, there is some difference between 278 
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the tools and criteria used. For example, low BMI (<18.5 kg/m2) was seen in one of those 279 
patients. By using ISS that criteria alone gave him 4 points, which is the cut-off for being at 280 
nutritional risk, and he was diagnosed as malnourished by ESPEN (Fact box, alternative 1). 281 
However, by using NRS-2002 he only was allocated only 1 point for the low BMI and 1 point 282 
for COPD, giving him a total score of 2 points (≥3 is considered at nutritional risk). Although 283 
many tools have been developed and implemented in different patient groups, there is no 284 
consensus on which tool is the most optimal. Recent meta-analysis concluded that it´s more 285 
important to do the screening for nutritional risk than the screening tool itself (van Bokhorst-de 286 
van der Schueren, Guaitoli, Jansma, & de Vet, 2014).  287 
One of the strengths of our study is that the study population is well defined i.e. hospitalised 288 
patients with COPD. However, a relatively small sample size is a limiting factor. Although, 289 
statistically significant associations with being ‘at nutritional risk’ or being malnourished were 290 
found for only a few of the outcomes assessed in our study, we cannot rule out associations 291 
previously seen in other studies. In our study, unintentional weight loss was the only component 292 
of the ESPEN criteria significantly associated with increased risk of mortality, although the 293 
association did not remain significant after adjustment. Unintentional weight loss has previously 294 
been associated with higher mortality in patients with COPD (Prescott et al., 2002). 295 
Our study describes the prevalence of malnutrition in hospitalized patients with COPD using the 296 
ESPEN criteria proposed in 2015. Our findings suggest that FFMI could be used independently 297 
of weight loss for the diagnosis of malnutrition in COPD patients, although there remain some 298 
problems associated with its measurement in the clinical setting. 299 
 300 
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Fact box 
The ESPEN diagnosis of malnutrition may be applied after patients have been screened using a validated 
screening tool to identify those at nutritional risk  
Alternative 1:   
- BMI < 18.5 kg/m2  
Alternative 2:   
- Weight loss (Unintentional) >10% indefinite of time, or >5% over the last 3 months combined with either   
- BMI <20 kg/m2 if <70 years of age, or <22 kg/m2 if ≥70 years of age or   
- FFMI <15 and 17 kg/m2 in women and men, respectively   
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Baseline characteristics   
  N=121 
Age (years), mean (SD) 73.7 (9.0) 
Gender   
   Male, n (%) 52 (43) 
   Female, n (%) 69 (57) 
Height (cm), mean (SD) 168.2 (9.4) 
Weight (kg), mean (SD) 72.7 (20.5) 
Weight loss, n (%)* 16 (13) 
   >10% indefinite of time 13 (81) 
   >5% over the last 3 months 3 (19) 
Body mass index (kg/m2), mean (SD) 25.7 (6.7) 
   ˂18.5 kg/m2, n (%) 19 (16) 
   18.5-24.9 kg/m2, n (%) 43 (36) 
   25.0-29.9 kg/m2, n (%) 26 (21) 
   ˃30.0 kg/m2, n (%) 33 (27) 
Body fat mass (kg), mean (SD) 22.4 (14.0) 
Fat free mass (kg), mean (SD) 50.4 (12.0) 
Fat free mass index (kg/m2), mean (SD) 17.7 (3.3) 
Low FFMI, n (%)† 36 (30) 
     FFMI ˂15 female, n (%) 20 (56) 
     FFMI ˂17 male, n (%) 16 (44) 
FEV1 (% of predicted), mean (SD)‡ 45.7 (20.9) 
Gold stage   
   Stage I (mild), n (%) 7 (7) 
   Stage II (moderate), n (%) 35 (36) 
   Stage III (severe), n (%) 35 (36) 
   Stage IV (very severe), n (%) 21 (21) 
 
                                                          
*
 Unintentional weight loss >10% indefinite of time, or >5% over the last 3 months  
†
 FFMI < 15 for female and < 17 for male 
‡
 n=98 
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Figure 1 Study flow chart 
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Table 2. The number of patients being at risk of malnutrition by two screening tools and diagnosed as malnourished 
according to the new ESPEN criteria 
  At risk (ISS)§  At risk (NRS-2002)**  Malnourished (ESPEN)††  
  n=44 n=67 n=25 
Age (years), mean (SD) 76.0 (8.9) 75.8 (9.1) 74.8 (9.3) 
Gender       
   Male, n (%) 19 (43) 30 (45) 12 (48) 
   Female, n (%) 25 (57) 37 (55) 13 (52) 
Height (cm), mean (SD) 168.0 (11.1) 169.2 (10.5) 170.0 (9.5) 
Weight (kg), mean (SD) 56.9 (14.2) 67.0 (19.0) 51.2 (8.1) 
Weight loss, n (%)‡‡ 16 (36) 15 (22) 10 (40) 
Body mass index (kg/m2), mean (SD) 20.1 (4.6) 23.3 (6.2) 17.7 (1.9) 
   ˂18.5 kg/m2, n (%) 19 (43) 18 (27) 19 (76) 
   18.5-24.9 kg/m2, n (%) 20 (46) 25 (37) 6 (24) 
   25.0-29.9 kg/m2, n (%) 4 (9) 15 (22) 0 (0) 
   ˃30.0 kg/m2, n (%) 1 (2) 9 (13) 0 (0) 
Body fat mass (kg), mean (SD) 12.6 (9.0) 18.7 (12.7) 9.2 (4.5) 
Fat free mass (kg), mean (SD) 44.3 (10.8) 48.3 (11.4) 42.0 (8.2) 
Fat free mass index (kg/m2), mean (SD) 15.6 (2.9) 16.7 (2.9) 14.4 (1.6) 
Low FFMI, n (%)§§ 28 (64) 28 (42) 21 (84) 
     FFMI ˂15 female, n (%) 15 (54) 15 (54) 10 (48) 
     FFMI ˂17 male, n (%) 13 (46) 13 (46) 11 (52) 
FEV1 (% of predicted), mean (SD)*** 40.3 (17.5) 42.6 (19.2) 35.2 (12.2) 
Gold stage       
   Stage I (mild), n (%) 1 (3) 3 (5) 0 (0) 
   Stage II (moderate), n (%) 8 (23) 18 (31) 2 (11) 
   Stage III (severe), n (%) 18 (51) 26 (44) 11 (58) 
   Stage IV (very severe), n (%) 8 (23) 12 (20) 6 (32) 
ESPEN proposed diagnostic criteria    
Alternative 1    
   BMI < 18.5 kg/m2, n (%) 19 (43) 18 (27) 19 (76) 
Alternative 2    
   Weight loss (unintentional) + low BMI, n (%) 9 (20) 9 (13) 9 (36) 
   Weight loss (unintentional) + low FFMI, n (%) 7 (16) 6 (9) 7 (28) 
Total number of subjects diagnosed malnourished when 
applying alternative 1 and/or 2, n (%) 25 (57) 23 (34) 25 (100) 
                                                          
§
 Icelandic screening sheet (ISS). At risk: score of ≥ 4, not at risk: score of ≤ 3 
**
 Nutritional risk screening (NRS-2002). At risk: score of ≥ 3, not at risk: score of ≤ 2 
††
 Screened at nutritional risk using ISS before applying the ESPEN criteria 
‡‡
 Unintentional weight loss >10% indefinite of time, or >5% over the last 3 months 
§§
 FFMI < 15 for female and < 17 for male 
***
 At risk (ISS) n=35, At risk (NRS-2002) n=59, Malnourished (ESPEN) n=19 
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Table 3. Linear regression analyses of nutritional risk assessed by two screening tools and malnutrition diagnose according to ESPEN new criteria, and COPD 
severity, length of stay > 7 days, 30-day readmission and mortality at 6 and 9 months. Unadjusted and adjusted results.  
Severe or very severe stage of disease (chronic obstructive pulmonary disease)j 
        
  
 Model 1k   Model 2l       
  
n OR 95% CI P-value OR 95% CI P-value       
At risk (ISS) 35 2.263 1.063 4.818 0.034 2.264 1.063 4.822 0.034 
        
At risk (NRS-2002) 59 2.621 1.245 5.515 0.011 2.612 1.241 5.500 0.011 
        
Malnourished (ESPEN) 19 3.106 1.221 7.902 0.017 3.091 1.214 7.871 0.018 
        
    Unintentional weight loss 12 0.889 0.308 2.564 0.828 0.888 0.308 2.563 0.826 
        
    Low age related BMI 31 3.226 1.443 7.210 0.004 3.217 1.435 7.216 0.005 
        
    Low FFMI 30 4.767 2.029 11.200 <0.001 4.761 2.026 11.190 <0.001 
        
Length of stay (LOS) more than 7 days 
  
 Model 1l   Model 2m   Model 3m   
  
n OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
At risk (ISS) 44 1.870 0.780 4.481 0.161 1.936 0.787 4.763 0.150 2.020 0.722 5.655 0.181 
At risk (NRS-2002) 67 1.594 0.718 3.537 0.252 1.566 0.688 3.564 0.285 1.637 0.646 4.145 0.299 
Malnourished (ESPEN) 25 2.386 0.753 7.560 0.139 2.326 0.715 7.562 0.160 1.573 0.444 5.571 0.482 
    Unintentional weight loss 16 0.839 0.268 2.626 0.743 0.821 0.252 2.671 0.743 0.730 0.194 2.748 0.642 
    Low age related BMI 38 2.135 0.834 5.466 0.114 1.983 0.756 5.200 0.164 2.013 0.686 5.910 0.203 
    Low FFMI 36 2.456 0.916 6.586 0.074 2.525 0.918 6.943 0.073 1.966 0.635 6.086 0.241 
 
 
 
 
      
 
 
         
 
 
 
             
 
             
                                                          
OR: Odd ratio, CI: confidence interval  
j
 Severe stage: 30 percent ≤ FEV1 <50 percent predicted. Very severe: FEV1 <30 percent predicted 
k
 Unadjusted 
l
 Adjusted for sex 
n Adjusted for sex and lung function 
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Readmission within 30 days 
  
 Model 1l   Model 2m   Model 3n   
  
n OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
At risk (ISS) 44 1.216 0.493 2.999 0.672 1.216 0.493 2.998 0.672 0.974 0.319 2.974 0.963 
At risk (NRS-2002) 67 1.955 0.771 4.959 0.158 1.953 0.769 4.957 0.159 1.767 0.559 5,585 0.332 
Malnourished (ESPEN) 25 0.950 0.317 2.845 0.927 0.947 0.316 2.839 0.922 0.483 0.097 2.400 0.374 
    Unintentional weight loss 16 2.716 0.879 8.386 0.082 2.715 0.879 8.384 0.083 1.706 0.407 7.143 0.465 
    Low age related BMI 38 0.815 0.308 2.156 0.681 0.809 0.305 2.150 0.671 0.511 0.144 1.819 0.300 
    Low FFMI 36 1.437 0.567 3.643 0.444 1.436 0.567 3.641 0.446 1.133 0.342 3.758 0.838 
Mortality within 6 months 
  
 Model 1l   Model 2m   Model 3n   
  
n OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
At risk (ISS) 44 3.480 1.168 10.368 0.025 3.528 1.175 10.590 0.025 2.744 0.731 10.303 0.135 
At risk (NRS-2002) 67 1.925 0.625 5.926 0.254 1.890 0.611 5.851 0.269 1.835 0.467 7.208 0.384 
Malnourished (ESPEN) 25 2.716 0.879 8.386 0.082 2.646 0.850 8.234 0.093 1.169 0.209 6.526 0.859 
    Unintentional weight loss 16 3.884 1.138 13.260 0.030 3.945 1.141 13.647 0.030 1.747 0.319 9.560 0.520 
    Low age related BMI 38 1.857 0.635 5.429 0.258 1.761 0.597 5.197 0.305 1.685 0.411 6.904 0.469 
    Low FFMI 36 2.038 0.695 5.981 0.195 2.029 0.687 5.993 0.200 1.591 0.390 6.491 0.517 
Mortality within 9 months 
  
 Model 1l   Model 2m   Model 3n   
  
n OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value 
At risk (ISS) 44 2.875 1.057 7.821 0.039 2.895 1.059 7.909 0.038 1.888 0.550 6.476 0.312 
At risk (NRS-2002) 67 1.465 0.533 4.023 0.459 1.442 0.523 3.974 0.479 1.077 0.321 3.621 0.904 
Malnourished (ESPEN) 25 2.722 0.941 7.874 0.065 2.668 0.918 7.752 0.071 0.917 0.171 4.931 0.920 
    Unintentional weight loss 16 2.955 0.892 9.785 0.076 2.971 0.891 9.909 0.076 1.394 0.261 7.438 0.697 
    Low age related BMI 38 1.745 0.639 4.770 0.278 1.677 0.609 4.616 0.317 1.230 0.320 4.730 0.763 
    Low FFMI 36 1.922 0.701 5.273 0.204 1.913 0.694 5.268 0.210 1.197 0.309 4.636 0.795 
OR: Odd ratio, CI: confidence interval  
l Unadjusted 
m
 Adjusted for sex 
n
 Adjusted for sex and lung function 
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Supplemental table 4:  
 
Table 4. Main characteristics in patients with low FFMIn         
  Not at nutritional risk At nutritional risko   
  n=8 n=28 P-value 
Age (years), mean (SD) 70.3 (10.5) 76.3 (8.9) 0.111 
Gender       
   Male, n (%) 3 (38) 13 (46)   
   Female, n (%) 5 (62) 15 (54)   
Height (cm), mean (SD) 169.9 (8.4) 167.6 (10.0) 0.558 
Weight (kg), mean (SD) 67.6 (6.7) 50.4 (7.2) <0.001 
Weight loss, n (%)p 0 (0) 7 (25)  
Body mass index (kg/m2), mean (SD) 23.5 (2.6) 17.9 (2.0) <0.001 
   ˂18.5 kg/m2, n (%) 0 (0) 18 (64)   
   18.5-24.9 kg/m2, n (%) 6 (75) 10 (36)   
   25.0-29.9 kg/m2, n (%) 2 (25) 0 (0)   
   ˃30.0 kg/m2, n (%) 0 (0) 0 (0)   
Body fat mass (kg), mean (SD) 23.3 (6.1) 10.9 (5.5) <0.001 
Fat free mass (kg), mean (SD) 44.3 (6.6) 39.5 (7.4) 0.106 
Fat free mass index (kg/m2), mean (SD) 15.3 (1.1) 13.9 (1.4) 0.016 
FEV1 (% of predicted), mean (SD)q 37.3 (38.4) 35.1 (15.1) 0.824 
Gold stage       
   Stage I (mild), n (%) 1 (14) 0 (0)   
   Stage II (moderate), n (%) 0 (0) 3 (13)   
   Stage III (severe), n (%) 2 (29) 13 (57)   
   Stage IV (very severe), n (%) 4 (57) 7 (30)   
 
                                                          
n
 FFMI < 15 for female and < 17 for male 
o
 At risk: score of ≥ 4, not at risk: score of ≤ 3 
p
 Unintentional weight loss >10% indefinite of time, or >5% over the last 3 months 
q
 Not at nutritional risk n=7, at nutritional risk n=23 
 
 
 
 
 
